{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-25-044098","form_type":"8-K","ticker":"ATOS","cik":"0001488039","company_name":"ATOSSA THERAPEUTICS, INC.","filed_at":"2025-03-25T23:59:59+00:00","discovered_at":"2026-05-14T18:03:03.760636+00:00","generated_at":"2026-05-24T05:39:36.543929+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Atossa Therapeutics ends 2024 with $71.1M cash; advances (Z)-endoxifen for metastatic breast cancer","bullets":["Cash and equivalents $71.1M, no debt; operating expenses fell to $27.6M from $31.4M in 2023.","Strategic pivot to pursue metastatic breast cancer indication for (Z)-endoxifen, citing streamlined regulatory path.","Phase 2 EVANGELINE trial of (Z)-endoxifen showed Ki-67 ≤10% response rate >85% across doses; amended protocol to compare 40mg + OFS vs exemestane + OFS.","Phase 2 KARISMA-Endoxifen: 1mg and 2mg doses reduced mammographic breast density by 17.3 and 23.5 percentage points (p<0.01) vs placebo 0.27 pts.","R&D expenses down 19% to $14.1M; G&A expenses down 4% to $13.5M."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-25-044098","json":"https://secwatch.observer/filing/0000950170-25-044098.json","markdown":"https://secwatch.observer/filing/0000950170-25-044098.md","text":"https://secwatch.observer/filing/0000950170-25-044098.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025044098/0000950170-25-044098-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1488039/000095017025044098/atos-20250325.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-24T05:39:36.543929+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}